International Journal of Science and Research (IJSR) ISSN: 2319-7064

SJIF (2019): 7.583

A Controlled Clinical Trial to Evaluate the Efficacy of Gandharvahastadi Kalka in the Management of Mutrashmari vis-à-vis Urolithiasis

Shrutika Gadale¹, Dr. Gajanana Hegde², Dr. V Rajendra³

¹PG Scholar, Department of Kayachikitsa, Government Ayurveda Medical College, Mysuru, India
E-mail: shrutikagadale046[at]gmail.com

²Professor, Department of PG studies in Kayachikitsa, Government Ayurveda Medical College, Mysuru, India
E-mail: dr.hegdegajanana[at]gmail.com

³Professor & Head, Department of PG studies in Kayachikitsa, Government Ayurveda Medical College, Mysuru, India
E-mail: swast_kutir[at]yahoo.com

Abstract: In Ayurvedic literatures Mutrashmari is considered as one among the Ashta Mahagada. The disease Mutrashmari resembles with that of Urolithiasis with respect to its signs and symptoms. Urolithiasis is the third most common affliction of the urinary tract with increased rate of recurrence. In Urolithiasis surgery will be the choice many a times, but those surgical procedures have limitations in various aspects. They are expensive and many a times leads to complications. Considering all these the present study was undertaken to evaluate the added effect of Gandharvahastadi kalka an Ayurveda formulation with good safety and efficacy profile. In the study, a result obtained in between the groups is statistically non-significant. However, Group A showed better result in reduction of number of calculi and symptoms such as basti shoola and mutra dharasanga. Whereas Group B showed better result in symptoms such as mutra daha and mutra krichra.

Keywords: Mutrashmari, Urolithiasis, Gandharvahastadi kalka.

1. Introduction

The formation of stone like substance within the *mutravaha* srotas is called as *Mutrashmari*¹. In *Ayurveda* literature *Mutrashmari* is considered as one among the *Ashta Mahagada*². This shows that the *Mutrashmari* disease prevailed since the inception of medicine in India.

Majority of signs and symptoms of the disease *Mutrashmari* resembles that of Urolithiasis. It is the third most common affliction of the urinary tract. The annual incidence is about 1-2 cases per 1000 people. Men are more commonly affected than female with a male to female ratio of 3:1. The peak age for developing calculi is between 30-50yrs, and recurrence is common ³. Without treatment, the typical patient has a 10% risk of recurrence at 1year, 35% at 5year and nearly 50% at 10years⁴.

The epidemiology of Urolithiasis differs according to geographical area in terms of prevalence and incidence, age and sex distribution, stone composition and stone location. Such differences have been explained in terms of race, diet and climate factors. Furthermore, changing socio-economic conditions have generated changes in the prevalence, incidence and distribution for age, sex and type of lithiasis in terms of both the site and the chemico-physical composition of the calculi⁵.

Nephrolithiasis is common worldwide. Globally, its incidence is increasing. An analysis from India shows an increase from 0.9% to 9.0% over 20 years. There is geographical variation in stone composition. The analysis from north India shows calcium oxalate is 93.4% (monohydrate is 80%, dehydrate is 20%), mixed is 2.76%, struvite is 1.42%, uric acid is 0.95%, cystine is 0.05%. In India, maximum prevalence occurs in Jammu and Kashmir,

Punjab, Haryana, Delhi, Rajasthan, Madhya Pradesh and Gujarat (stonebelt of India). ⁶

The treatment principle of Urolithiasis in contemporary science is flush therapy in case of stones up to 5mm, in larger stones the advanced procedures like ESWL (Extracorporeal shock wave lithotripsy) and operative procedures like PCNL (Percutaneous nephrolithotomy), Pyelolithotomy, Nephrolithotomy, Extended pyelolithotomy, Pyelo nephrolithotomy, Partial nephrectomy, Nephrectomy are done⁷. But these procedures have limitations in various aspects. They are expensive and many a times leads to complications such as injury to colon, injury to blood vessels and sepsis⁸.

On the other hand, many medicinal formulations mentioned in *Ayurvedic* literature for the management of *Mutrashmari*, are cost effective, devoid of complications and provide wide scope for the successful treatment of Urolithiasis. The *Ayurvedic* formulations *Nagaradi kashaya* mentioned in *Chakradatta*⁹, *Badarashma pishti* (hajarul yahud pishti) mentioned in *Rasamritam*¹⁰ and *Gandharvahastadi kalka* mentioned in *Astanga Hridaya*¹¹ are specifically indicated in *Mutrashmari* and the drugs of these *yogas* possess ashmaribhedana and mutrala properties. In addition to this it has kapha-vata pradhana tridoshaharaaction.

Hence the current study was undertaken as an attempt to evaluate the added effect of *Gandharvahastadi kalka* in the management of *Mutrashmari*.

In the present study, total of 70 subjects with each group consisting of 35 subjects of *Mutrashmari* via-a-vis Urolithiasis were incidentally selected.

Volume 9 Issue 11, November 2020

www.ijsr.net

<u>Licensed Under Creative Commons Attribution CC BY</u>

Paper ID: SR201104115329 DOI: 10.21275/SR201104115329 376

International Journal of Science and Research (IJSR) ISSN: 2319-7064

ISSN: 2319-7064 SJIF (2019): 7.583

Objective of the Study

To evaluate the efficacy of *Gandharvahastadi Kalka* in the management of *Mutrashmari* vis-a-vis Urolithiasis.

2. Materials and Methods

Materials

The materials used in the study were:

- Nagaradi kashaya- Shunthi, Varuna, Gokshura, Pashanabheda, Bhrami, Yavakshara, Guda
- 2) Badarashma pishti Badarashma
- 3) Gandharvahastadi kalka Eranda, Vyagri, Gokshura, Brahati, Ikshuraka

Source of Drugs and Method of preparation

Nagaradi kashaya, Badarashma pishti, Gandharvahastadi kalka were specifically prepared for the purpose of study and procured from S.N. Pandit Ayurvedic Co. Pvt. Ltd, Mysuru, (a GMP certified pharmacy).

Methods

Source of data

Subjects were selected from the OPD & IPD of Government Ayurveda Medical College & Hospital and Government Hitech Panchakarma Hospital, a teaching hospital of Government Ayurveda Medical College, Mysuru.

Study Design

A controlled clinical study with pre – post test design. Purposive sampling technique was employed.

Grouping

Subjects were assigned into two groups i.e., Group A (Control Group) and Group B (Trial Group).

Sample size

The study was completed in 70 subjects and the numbers of registered volunteers were 74 with 4 dropouts.

Duration of the intervention: 30 days

Inclusion criteria

- 1) All individuals irrespective of gender, between the age group of 18 to 60 years were included for the study.
- 2) The individual with or without the clinical features of *Mutrashmari*, diagnosed to be suffering from urinary calculi confirmed by Ultrasonography (USG) of Kidney, Ureter, Bladder (KUB) were included for the study.
- The individuals with solitary or multiple urinary calculi irrespective of number, location were included in the study.
- 4) Urinary calculi within the size of 8mm were only included in the study.
- 5) The individuals of Urolithiasis with mild to moderate Hydronephrosis were included for the study.
- 6) Both fresh and treated cases were taken for the study.

Exclusion criteria

- Subjects suffering from renal pathologies such as renal failure, severe hydronephrosis, pyonephrosis and renal tumors were excluded.
- 2) Individuals suffering from severe Haematuria.
- Volunteers with other obstructive diseases of urinary tract system like urethral stricture, CA ureter, CA prostate, meatal stenosis, bladder neck contracture were excluded.
- 4) The subjects with uncontrolled diabetes and with other major systemic disorders which interfere with the intervention were excluded.
- 5) Pregnant and lactating women were excluded.

Diagnostic criteria

Objective criteria

Ultrasonography (USG) of Kidney, Ureter, Bladder (KUB) region.

Signs and symptoms

Basti Shoola (pain in abdomen or loin)
Sarakta Mutra (haematuria)
Mutradaha (burning micturition)
Mutra dhara Sangha (obstruction in the flow of urine)
Mutrakrichra (difficulty in micturition).

Assessment criteria

Grading for the signs and symptoms is detailed below

Complete absence of signs and symptoms 0 Occasionally presence of signs and symptoms 1 Mild degree of the signs and symptoms 2 Moderate degree of the signs and symptoms 3 Severe degree of the signs and symptoms 4

Assessment was done before and after the interventions based on scoring of symptoms were as follows:

| S. No. | Subjective parameter | Grading |
|--------|----------------------|---------|
| 1. | Basti shoola | |
| | None | BS0 |
| | Occasionally | BS1 |
| | Mild | BS2 |
| | Moderate | BS3 |
| | Severe | BS4 |
| 2. | Mutra daha | |
| | None | Md0 |
| | Occasionally | Md1 |
| | Mild | Md2 |
| | Moderate | Md3 |
| | Severe | Md4 |
| 3. | Mutradhara sanga | |
| | None | Mds0 |
| | Occasionally | Mds1 |
| | Mild | Mds2 |
| | Moderate | Mds3 |
| | Severe | Mds4 |
| 4. | Sarakta mutrata | |
| | None | Srm0 |
| | Occasionally | Srm1 |
| | Mild | Srm2 |

Volume 9 Issue 11, November 2020

www.ijsr.net

<u>Licensed Under Creative Commons Attribution CC BY</u>

Paper ID: SR201104115329 DOI: 10.21275/SR201104115329 377

International Journal of Science and Research (IJSR)

ISSN: 2319-7064 SJIF (2019): 7.583

| | Moderate Severe | Srm3 Srm4 |
|----|--------------------|--------------|
| 5. | Mutrakrichrata | |
| | None | Mkr0 |
| | Occasionally | Mkr1 |
| | Mild | Mkr2 |
| | Moderate | Mkr3 |
| | Severe | Mkr4 |

Investigations

- 1) Subjects were diagnosed on the basis of Ultrasonography (USG) of the Kidney, Ureter, Bladder (KUB) region.
- 2) However investigations were conducted to rule out other systemic disorders, investigations such as Hb%, TC, DC, ESR, Urine sugar, albumin and microscopic examination.

Statistical methods

The results were analyzed statistically by using Chi square test and descriptive statistics using service for statistical solution (SPSS) for windows software.

Intervention

Group A

Control group, following intervention were done -

- 1) *Nagaradi Kashaya:* 100ml in two equally divided dose and *Yavakshara* 350mg in each dose with *Guda*.
- 2) Badarashma Pishti: 1gm in two equally divided dose with honey as Anupana.

Group B

Trial group, following intervention were done -


- 1) Gandharvahastadi Kalka: 12gm in two equally divided dose with Madhura Dadhi as Anupana.
- 2) Nagaradi Kashaya: 100ml in two equally divided dose and Yavakshara. 350mg in each dose with Guda.
- 3) Badarashma Pishti: 1gm in two equally divided dose with honey as Anupana.

Duration of intervention: 30 days before food.

3. Observations and Results

The data regarding the samples were collected based on the diagnostic criteria and scoring given to each of the symptoms. The symptoms were assessed using the parameters and ultrasonography of KUB region was done, before intervention on 0 day and after the intervention on 31st day.


Results of Basti shoola



Among 70 subjects, 30 individuals in group A and 31 in group B had severe *basti shoola* before intervention. After intervention 35 volunteers in group A and 33 in group B were completely relieved from *basti shoola* whereas 2 clients in group B had mild symptom. Group A showed

100% remission in *basti shoola* and Group B showed 94.3% remission.

Results on Mutradaha



Volume 9 Issue 11, November 2020

www.ijsr.net

<u>Licensed Under Creative Commons Attribution CC BY</u>


Paper ID: SR201104115329 DOI: 10.21275/SR201104115329

International Journal of Science and Research (IJSR)

ISSN: 2319-7064 SJIF (2019): 7.583


Before intervention in Group A 16 volunteers and 13 in Group B had severe *mutradaha* whereas 14 individuals in Group A and 8 in Group B had occational symptom. After intervention in Group A, 1 individual had *mutradaha*. Group B showed 100% remission whereas Group A with 97.1%.

Result on Mutra dhara sanga



Before intervention in both the groups 13-14 subjects had occational *mutra dhara sanga* whereas 3-4 individuals had severe symptom. After intervention in Group A 100% remission was seen in the subjects and 97.1% in Group B.


Results on Sarakta Mutra



Out of 70 subjects before intervention, in Group A, 2 (5.7%) subjects had severe *sarakta mutra* and 1 (2.9%) with occational *sarakta mutra*, where as in Group B, 1 (2.9%) subject had severe *sarakta mutra* and 4 (11.4%) with occational *sarakta mutra*. After the intervention all the individuals were relieved from the symptom *sarakta mutra*.

There was no statistically significant result in between the groups, however according to percentage, both the group showed 100% remission.

Result on Mutrakrichra



Among 70 subjects, 16 in Group A and 12 in Group B had occational mutrakrichra, 5-7 subjects in both groups had severe symptom, 3-5 individuals had moderate symptom in both the group and 4-7 clients had mild mutrakrichra

before intervention. After intervention 88.6% in Group A and 91.4% in Group B got complete remission of symptom.

Result on number of calculus in subjects of Mutrashmari

379


Volume 9 Issue 11, November 2020 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

Paper ID: SR201104115329 DOI: 10.21275/SR201104115329

International Journal of Science and Research (IJSR)

ISSN: 2319-7064 SJIF (2019): 7.583



Out of 70 subjects 19 in Group A and 6 in Group B had single calculus, 6 in Group A and 14 in Group B had two calculi, 4 clients in Group A and 3 in Group B had three calculi, 3 individuals in both the Groups had four stones and more than four stones was seen in 3 subjects in Group A and 9 individuals in Group B was seen before intervention. After intervention

4. Results

In the present study, a result obtained in between the groups is non-significant. However, Group A showed better result in reduction of number of calculi and symptoms such as *basti shoola* and *mutra dhara sanga*. Whereas Group B showed better result in symptoms such as *mutra daha* and *mutra krichra*.

5. Conclusion

The combination of these drugs acts as *mutrala*, *ashmarihara* and *tridoshahara*. With the obtained results it can be concluded that the *Nagaradi kashaya*, *Badarashma pishti* and *Gandharvahastadi kalka* can be safely and effectively carried out in subjects of *Mutrashmari* with better results.

References

- [1] Raja Radha Kantadeva, Shabda Kalpa Druma, part 1, 3rd edition (1967), publisher- Chaukhamba Sanskrit series, pp- 141.
- [2] Vaidya Jadavji Trikamji Acharya, Sushruta Samhita of Sushruta with Nibandhasangraha commentary of Sri Dalhanacharya, edition reprint (2014), Sutra Sthana 33/4,5, publisher- Chaukhamba Surabharati Prakashan, Varanasi, pp- 144.
- [3] http://www.patient.co.uk/doctor/urinary-tract-stonesurolithiasis
- [4] Yash Pal Munjal, API Text Book of Medicine, 9thedition (2012) volume 2, section- 19, published & distributed by- Jaypee Brothers medical publishers (p) Ltd, New Delhi, pp- 1319.
- [5] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC278120
- [6] Y.P.Munjal, API textbook of medicine, Jaypee Brothers Medical Publishers, New delhi, 9th edition, vol-2 section 19,pp.1318.

- [7] K. Rajgopal Shenoy, Manipal Manual of Surgery, 2nd edition reprint (2009), chapter- 39, published by- CBS publisher & distributors (pvt) Ltd, New Delhi, pp- 618.
- [8] M. Sriram Bhat, SRB's Manual of Surgery, 4th edition, chapter- 26, published & distributed by- Jaypee Brothers medical publishers (p) Ltd, New Delhi, pp- 1092.
- [9] Prof. Ramanath Dwivedy, Chakradatta of Sri Chakrapanidatta with Vaidayaprabha (hindi) commentary by Dr. Indradeva Tripathi, edition reprint (2015), chapter- 34/28, publisher- Chaukhamba Surabharati Bhawan, Varanasi, pp- 212.
- [10] Dr. Damodar Joshi, Rasamritam of Vaidya Jadavji Trikamji Acharya, English translation, 2nd edition (2003), publisher- Chaukhamba Surabharati Bhawan, Varanasi, pp- 127.
- [11] Pt. Hari Sadasiva Sastri Paradakara Bhisagacharya, Astanga Hridaya of Vagbhata with commentaries Sarvangasundara of Arunadatta and Ayurvedarasayana of Hemadri, edition reprint (2016), Chikitsa Sthana 11/21, publisher- Chaukhamba Surabharati Prakashan, Varanasi, pp- 674.

Volume 9 Issue 11, November 2020 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

Paper ID: SR201104115329 DOI: 10.21275/SR201104115329 380